Thymosin Alpha-1
28-residue thymic peptide and approved immunomodulator with a comprehensive clinical literature.
Available sizes
| SKU | Per vial | Pack | |
|---|---|---|---|
| TA5 | 5 mg | 10 vials / box | |
| TA10 | 10 mg | 10 vials / box |
Order Thymosin Alpha-1
Pricing is quoted directly and is competitive at every tier — message us with the SKUs you want and quantities for a quote.
Replies within 36 hours. Cryptocurrency (preferred) or card / money-app with a processing fee. COA for this batch available on request.
Thymosin α1 is a 28-amino-acid acetylated peptide originally isolated from thymic tissue. It modulates innate and adaptive immunity through Toll-like receptors on dendritic cells, promoting T-cell maturation and Th1 cytokine responses.
As thymalfasin it is approved in more than 30 countries for hepatitis B and as a vaccine adjuvant; a comprehensive review summarises its clinical use across viral infection, immunodeficiency, sepsis and oncology adjunct settings 1.
At a glance
- TLR-mediated immunomodulator; approved drug in many markets
- Studied in hepatitis, sepsis, oncology and vaccine-adjuvant roles
- 5 mg and 10 mg vials
- Form
- Lyophilized powder
- Purity
- HPLC-verified — Certificate of Analysis available on request
- Pack size
- Box of 10 vials
- Storage
- Lyophilized: −20 °C, protected from light (2–8 °C short-term). Reconstituted: 2–8 °C.
- Formula
- C129H215N33O55
- Mol. weight
- 3108.3 g/mol
- CAS No.
- 62304-98-7
Sequence, formula and CAS data are provided for identification. Batch-specific purity, mass-spec and HPLC data are on the Certificate of Analysis — ask for it with your order.
- Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78.
Citations retrieved from PubMed (NCBI). Links open the publisher record via DOI and the PubMed abstract.